⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440352 | 1.00 | — | — | |
| SCHEMBL265423 | 1.00 | — | — | |
| SCHEMBL8115501 | 1.00 | — | — | |
| SCHEMBL1375335 | 1.00 | — | — | |
| SCHEMBL1688785 | 1.00 | — | — | |
| SCHEMBL5521450 | 1.00 | — | — | |
| SCHEMBL30287516 | 1.00 | — | — | |
| SCHEMBL438545 | 1.00 | — | — | |
| SCHEMBL10441953 | 0.97 | GABRR1 (0.48) | — | |
| SCHEMBL5500131 | 0.97 | GABRR1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118878557-A | Pan-KRAS inhibitor compound | 杭州阿诺生物医药科技有限公司 | 2024-11-01 | — | — | CN | claimed |
| WO-2026098567-A1 | MACROCYCLIC COMPOUNDS AND USE THEREOF | 微境生物医药科技(上海)有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4720072-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260078133-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2026-03-19 | — | — | US | disclosed |
| US-20260078134-A1 | Macrocyclic Compounds as RAS Inhibitors | BEONE MEDICINES I GMBH (CH) | 2026-03-19 | — | — | US | disclosed |
| EP-4695233-A2 | SYNTHESIS OF RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4653438-A1 | MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-12465643-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| US-8063215-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| US-20100152151-A1 | TGR5 MODULATORS AND METHODS OF USE THEROF | INTERCEPT PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152151-A1 | TGR5 MODULATORS AND METHODS OF USE THEROF | INTERCEPT PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010059853-A1 | TGR5 MODULATORS AND METHOD OF USE THEREOF | INTERCEPT PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20100105682-A1 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-04-29 | — | — | US | disclosed |
| US-20100063080-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-11 | — | — | US | disclosed |
| US-20100063080-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-11 | — | — | US | disclosed |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| WO-2008063669-A1 | HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080119464-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC. | 2008-05-22 | — | — | US | disclosed |